Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm everolimus study in refractory metastatic colorectal adenocarcinoma
2006-003255-20Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in colorectal adenocarcinoma and Intestinal adenocarcinoma, sponsored by Novartis. Primary endpoints: Disease control rate and Objective response rate. Started May 2007; status: completed.
02
Drugs
everolimus
03
Conditions
colorectal adenocarcinomaIntestinal adenocarcinoma
Beyond the preview
Go deeper on 2006-003255-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003255-20.